Viral transduction of CD34+ cells is a promising approach for treating inherited disorders such as sickle cell disease, ß-thalassemia, or primary immunodeficiencies. An automated and functionally closed system can provide the necessary environment for GMP-compliant manufacturing of such cell therapy products.
This webinar explores Miltenyi Biotec’s automated Hematopoietic Stem Cell (HSC) Engineering process, facilitated by the CliniMACS Prodigy® Cell Manufacturing Platform.
The CliniMACS Prodigy HSC Engineering process automates the manufacturing of gene-engineered HSCs by viral transduction of human CD34+ cells. All steps are automated with manufacturing taking place in sterile, single-use tubing sets, ensuring highly reproducible and standardized manufacturing processes.